GINA DEBLASIO: Open Payments
NPI 1710391784 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 44 payments from 15 companies in 2025. Trend: 2023 $1,486 · 2024 $1,065 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $199 |
| UCB, Inc. | 5 | $119 |
| Journey Medical Corporation | 1 | $83 |
| Amgen Inc. | 3 | $78 |
| Novartis Pharmaceuticals Corporation | 3 | $70 |
| Galderma Laboratories, L.P. | 4 | $63 |
| PFIZER INC. | 3 | $62 |
| Incyte Corporation | 2 | $48 |
| REVANCE THERAPEUTICS, INC. | 1 | $46 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $45 |
Products named: SKYRIZI, Bimzelx, OTEZLA, NEMLUVIO, CIBINQO, RINVOQ, OPZELURA, DAXXIFY.
Industry payments across VA — which companies pay providers there.
